Molecular Partners Ag (MOLN) Cash & Equivalents (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Cash & Equivalents of $82048.8 for Q1 2026, down 100.0% year-over-year from $90.5 billion in Q1 2025, and up 79240.97% quarter-over-quarter from $103.41 in Q4 2025.
Molecular Partners Ag (MOLN) Cash & Equivalents (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Cash & Equivalents for 7 consecutive years, with $82048.8 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 100.0% year-over-year to $82048.8; the TTM figure through Mar 2026 stood at $82048.8 (down 100.0% YoY), while the FY2025 annual figure was $103.41, down 100.0% from the prior year.
- Cash & Equivalents advanced to $82048.8 in Q1 2026 per MOLN's latest filing, from $103.41 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $153.8 billion in Q1 2022 and bottomed at $99.02 in Q2 2025.
- Historically, Cash & Equivalents has averaged $37.0 billion across 5 years, with a median of $91.3 million in 2022.
- Annual changes were most pronounced in 2022 — Cash & Equivalents grew 17.22% — and 2026, when it sank 100.0%.
- Molecular Partners Ag's Cash & Equivalents stood at $91.3 million in 2022, then dropped by 16.88% to $75.9 million in 2023, then dropped by 3.91% to $72.9 million in 2024, then tumbled by 100.0% to $103.41 in 2025, then jumped by 79240.97% to $82048.8 in 2026.
- Business Quant data shows MOLN's Cash & Equivalents at $82048.8 in Q1 2026, $103.41 in Q4 2025, and $102957.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 82,048.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82,048.83 |
| Dec 31, 2025 | 103.41 |
| Sep 30, 2025 | 102,957.77 |
| Jun 30, 2025 | 99.02 |
| Mar 31, 2025 | 90.50 Bn |
| Dec 31, 2024 | 72.91 Mn |
| Sep 30, 2024 | 75.89 Bn |
| Jun 30, 2024 | 70.84 Mn |
| Mar 31, 2024 | 78.30 Bn |
| Dec 31, 2023 | 75.88 Mn |
| Sep 30, 2023 | 77.44 Bn |
| Jun 30, 2023 | 70.34 Mn |
| Mar 31, 2023 | 79.93 Bn |
| Dec 31, 2022 | 91.29 Mn |
| Sep 30, 2022 | 72.17 Bn |
| Jun 30, 2022 | 119.34 Mn |
| Mar 31, 2022 | 153.78 Bn |
| Dec 31, 2021 | 77.88 Mn |
| Sep 30, 2021 | 90.29 Bn |
| Jun 30, 2021 | 138.80 Mn |